Home › Opioid Overdose › NCT06639464
Semaglutide for Helping Opioid Recovery
Semaglutide for the Treatment of Opioid Use Disorder: A Pilot Randomized Controlled Trial
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria * English-speaking adults aged 18 or older * DSM-5 diagnosis of severe opioid use disorder (OUD) * Receiving buprenorphine ≥16 mg/day or methadone ≥70 mg/day for at least 30 days prior to enrollment * Planning to continue buprenorphine or methadone treatment throughout the study * Willing to bring buprenorphine prescriptions to visits for dose counts (if applicable) * Willing to authorize communication between the study team and their MOUD prescriber via a 42 CFR release Exclusion Criteria * Active psychosis, suicidality, homicidality, or psychiatric conditions impairing capacity to consent * Current or lifetime history of an eating disorder * BMI \<21 kg/m² * Current or lifetime diagnosis of Type 1 or Type 2 diabetes * Personal or family history of medullary thyroid carcinoma or MEN2 * GLP-1 receptor agonist use within the past 3 months or anticipated use during the study * Myocardial infarction, stroke, unstable angina, or congestive heart failure within the past 90 days * Persistently elevated BP (\>160 mmHg systolic or \>100 mmHg diastolic) during screening * History of inflammatory bowel disease, bariatric surgery, idiopathic pancreatitis, or diabetic gastroparesis * Liver function tests \>3x the upper limit of normal or eGFR \<30 * History of hypersensitivity or allergy to semaglutide * Pregnancy or breastfeeding * Anticipated participation in another investigational drug trial * Any other condition that investigators determine may interfere with participation or pose a safety concern
About the study
The is a pilot, 12-week, double-blind, placebo-controlled, randomized trial of individuals with opioid use disorder (OUD) newly initiating buprenorphine to receive either weekly injections of semaglutide (n=23) or matching placebo (n=23). The primary aim is to determine the effects of semaglutide on cue-reactivity among individuals with OUD. The secondary aim is to assess the preliminary efficacy, safety, and tolerability of semaglutide for OUD.
What is being tested
- Semaglutide (drug)
- Placebo (other)
Sponsor: Brigham and Women's Hospital · Participants: 46 · Started: Jun 2, 2025
Contact the study team
- Joji Suzuki · Phone: 617-732-5752
Official record on ClinicalTrials.gov — NCT06639464
Locations in the U.S.
| Massachusetts | Brigham and Women's Hospital, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.